Development of a high-throughput 3D culture microfluidic platform for multi-parameter phenotypic and omics profiling of patient-derived organoids
Botrugno, O. A.; Bianchi, E.; Bruno, J. M.; Felici, C.; Gallo, G. F. M.; Sommella, E. M.; Merciai, F.; Caponigro, V.; Golino, V.; La Gioia, D.; De Stefano, P. D.; Giansanti, V.; Rossella, V.; Lazarevic, D.; Colombo, E.; Falletta, P.; Giovannoni, G.; Gatti, G.; Ratti, F.; Buonanno, S.; Pedica, F.; Tacchetti, C.; Zambrano, S.; Mazza, D.; Cittaro, D.; Campiglia, P.; Aldrighetti, L.; Tonon, G.; Dubini, G.
Show abstract
Patient-derived organoids (PDOs) are poised to become central tools both in clinical practice, to preemptively identify patient optimal treatments, and in drug discovery, overcoming the limitations of cancer cell lines. However, the use of PDOs in these settings has been hampered by several bottlenecks, including sample requirements, assay time, and handling in the context of high-throughput assays. We developed a Microfluidic Platform for Organoids culture (MPO) that miniaturises and simplifies PDOs cultures in a 384-plate format. Both retrospective and prospective clinical studies demonstrate MPO predictive value and the straightforward implementation in the clinical setting. MPO allows subcellular phenotypic screenings, as imaging-based applications like Cell Painting, target engagement analyses, alongside the comprehensive definition of PDOs genomic, transcriptomic, proteomic, lipidomic, and metabolomic landscapes. Harnessing the pleiotropic capabilities of MPO, we uncovered the role of EZH2 inhibitors to prevent the long-term emergence of resistance to RAS inhibitors in metastatic colon cancer. In all, we demonstrate the potential of MPO to impact clinical practice, alongside exploration of the mechanisms underlying compound response and resistance.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Drug screening at single-organoid resolution via bioprinting and interferometry 96%
- Combi-Seq: Multiplexed transcriptome-based profiling of drug combinations using 1deterministic barcoding in single-cell droplets 96%
- XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncology 95%
Similar papers in this journal
- Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models 94%
- Single-molecule systems for detection and monitoring of plasma circulating nucleosomes and oncoproteins in Diffuse Midline Glioma 94%
- Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments 94%
Similar papers in this journal
- Multiplexed drug testing of tumor slices using a microfluidic platform 95%
- A patient-derived ovarian cancer organoid platform to study susceptibility to natural killer cells 95%
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 94%
Similar papers in this journal
- A flexible microfluidic system for single-cell transcriptome profiling elucidates phased transcriptional regulators of cell cycle 94%
- A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens 93%
- Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration 92%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.